Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 5:39 PM
Ignite Modification Date: 2025-12-25 @ 3:09 PM
NCT ID: NCT00957268
Description: Safety set: All enrolled participants who received at least 1 dose of study drug. At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Frequency Threshold: 0
Time Frame: None
Study: NCT00957268
Study Brief: Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Alogliptin 12.5 mg (Age 10 to < 14 Years) Alogliptin 12.5 mg QD, tablets, orally, 1 dose only. None None 0 5 3 5 View
Alogliptin 25 mg (Age 10 to < 14 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only. None None 0 4 1 4 View
Alogliptin 12.5 mg (Age 14 to < 18 Years) Alogliptin 12.5 mg QD, tablets, orally, 1 dose only. None None 0 8 5 8 View
Alogliptin 25 mg (Age 14 to < 18 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only. None None 0 7 2 7 View
Alogliptin 25 mg (Age 18 to 65 Years) Alogliptin 25 mg QD, tablets, orally, 1 dose only. None None 0 22 9 22 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Abdominal pain SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (14.1) View
Gastritis SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (14.1) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (14.1) View
Vomiting SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (14.1) View
Fatigue SYSTEMATIC_ASSESSMENT General disorders MedDRA (14.1) View
Haematocrit decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA (14.1) View
Haemoglobin decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA (14.1) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (14.1) View
Presyncope SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (14.1) View
Rash papular SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (14.1) View
Nodule SYSTEMATIC_ASSESSMENT General disorders MedDRA (14.1) View
Tenderness SYSTEMATIC_ASSESSMENT General disorders MedDRA (14.1) View
Decreased appetite SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (14.1) View
Joint swelling SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (14.1) View
Tremor SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (14.1) View
Ecchymosis SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (14.1) View
Erythema SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (14.1) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (14.1) View
Pyrexia SYSTEMATIC_ASSESSMENT General disorders MedDRA (14.1) View
Viral infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (14.1) View
Blood creatine phosphokinase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (14.1) View
Neutrophil count decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA (14.1) View
Hypoglycaemia SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (14.1) View
Pain in extremity SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (14.1) View
Dysgeusia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (14.1) View